In addition, in the Targeted Agent and Profiling Utilization Registry (TAPUR) study, genomically matched treatment showed good clinical efficacy in the following five cohorts: pertuzumab and trastuzumab in ERBB2-amplified or overexpressed colorectal cancer [6], emurafenib and cobimetinib in BRAF V600E/D/K/-mutated colorectal cancer [7], pembrolizumab in metastatic breast cancer with a high mutational burden [8], pembrolizumab in metastatic colorectal cancer with a high mutational burden, and palbociclib in non-small cell lung cancer with CDKN2A alteration [9,10]. This evidence concerns the gene BRAF and colorectal cancer.